IL1B and non-small cell lung carcinoma: The CANOPY-1 study, a phase III randomized, double-blind trial, investigated the efficacy of adding canakinumab, a human monoclonal anti-IL-1β antibody, to a first-line treatment regimen of pembrolizumab and platinum-based chemotherapy for patients with advanced or metastatic non-small-cell lung cancer (NSCLC) without EGFR or ALK mutations.